📊 RANI Key Takeaways
Is Rani Therapeutics Holdings, Inc. (RANI) a Good Investment?
Early-stage biopharma with improving losses (down 27.5% YoY) but severe profitability challenges and unsustainable cash burn of $18.7M annually. With only $18.6M cash and ~12 months of runway at current burn, the company faces significant dilution risk and must achieve substantial revenue growth or secure additional financing to survive.
Why Buy Rani Therapeutics Holdings, Inc. Stock? RANI Key Strengths
- Zero long-term debt provides financial flexibility and eliminates refinancing risk
- Operating losses improving 27.5% YoY demonstrates progress toward profitability trajectory
- Strong current ratio of 4.21x with ample short-term liquidity to fund near-term operations
RANI Stock Risks: Rani Therapeutics Holdings, Inc. Investment Risks
- Approximately 12-month cash runway at current burn rate; no guaranteed funding sources
- Revenue of $1.6M vastly insufficient relative to $38.3M operating losses; product commercialization in earliest stages
- Negative free cash flow of -$18.8M annually unsustainable without exponential revenue growth or significant financing rounds
Key Metrics to Watch
- Quarterly sequential revenue growth rate to assess market adoption of oral drug delivery platform
- Operating cash burn rate trends and path to cash flow breakeven
- Gross margin emergence as revenue scales to validate business model unit economics
Rani Therapeutics Holdings, Inc. (RANI) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 4.21x current ratio provides a solid financial cushion.
RANI Profit Margin, ROE & Profitability Analysis
RANI vs Healthcare Sector: How Rani Therapeutics Holdings, Inc. Compares
How Rani Therapeutics Holdings, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Rani Therapeutics Holdings, Inc. Stock Overvalued? RANI Valuation Analysis 2026
Based on fundamental analysis, Rani Therapeutics Holdings, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Rani Therapeutics Holdings, Inc. Balance Sheet: RANI Debt, Cash & Liquidity
RANI Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Rani Therapeutics Holdings, Inc.'s revenue has declined by 40% over the 5-year period, indicating business contraction. The most recent EPS of $-1.05 indicates the company is currently unprofitable.
RANI Revenue Growth, EPS Growth & YoY Performance
RANI Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | N/A | -$5.4M | $-0.12 |
| Q2 2025 | N/A | -$6.7M | $-0.18 |
| Q1 2025 | N/A | -$7.3M | $-0.22 |
| Q3 2022 | N/A | -$3.1M | $-0.16 |
| Q2 2022 | N/A | -$7.6M | $0.31 |
| Q1 2022 | $756.0K | -$6.2M | N/A |
| Q3 2021 | N/A | -$2.7M | N/A |
| Q2 2021 | $60.0K | -$2.7M | N/A |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Rani Therapeutics Holdings, Inc. Dividends, Buybacks & Capital Allocation
RANI SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Rani Therapeutics Holdings, Inc. (CIK: 0001856725)
📋 Recent SEC Filings
❓ Frequently Asked Questions about RANI
What is the AI rating for RANI?
Rani Therapeutics Holdings, Inc. (RANI) has an AI rating of SELL with 48% confidence, based on fundamental analysis of SEC EDGAR filings.
What are RANI's key strengths?
Claude: Zero long-term debt provides financial flexibility and eliminates refinancing risk. Operating losses improving 27.5% YoY demonstrates progress toward profitability trajectory.
What are the risks of investing in RANI?
Claude: Approximately 12-month cash runway at current burn rate; no guaranteed funding sources. Revenue of $1.6M vastly insufficient relative to $38.3M operating losses; product commercialization in earliest stages.
What is RANI's revenue and growth?
Rani Therapeutics Holdings, Inc. reported revenue of $1.6M.
Does RANI pay dividends?
Rani Therapeutics Holdings, Inc. does not currently pay dividends.
Where can I find RANI SEC filings?
Official SEC filings for Rani Therapeutics Holdings, Inc. (CIK: 0001856725) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is RANI's EPS?
Rani Therapeutics Holdings, Inc. has a diluted EPS of $-0.45.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is RANI a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Rani Therapeutics Holdings, Inc. has a SELL rating with 48% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is RANI stock overvalued or undervalued?
Valuation metrics for RANI: ROE of -89.9% (sector avg: 15%), net margin of -1,817.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy RANI stock in 2026?
Our dual AI analysis gives Rani Therapeutics Holdings, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is RANI's free cash flow?
Rani Therapeutics Holdings, Inc.'s operating cash flow is $-18.7M, with capital expenditures of $88.0K. FCF margin is -1,151.4%.
How does RANI compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -1,817.1% (avg: 12%), ROE -89.9% (avg: 15%), current ratio 4.21 (avg: 2).